Back to search
FDAFDA · Food and drugs·Recall number D-0160-2024

ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only, Manufactured by GlaxoSmithKline Durham, NC 27701. NDC 0173-0869-10

Published January 3, 2024 · Recall initiated: December 12, 2023

Summary

FDA records drug Class III recall D-0160-2024, published January 3, 2024 and initiated December 12, 2023. Recalling firm: GlaxoSmithKline LLC; Status: Terminated; Reported quantity: 67,508 inhalers; Lot: Lot #: 7Y9S. Exp June 2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

What to do

Voluntary: Firm initiated · Letter

Get an email if ANORO ELLIPTA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ANORO ELLIPTA
Manufacturer
GlaxoSmithKline LLC
Distributor
Distributed Nationwide in the USA and Puerto Rico.
Lot
Lot #: 7Y9S. Exp June 2025
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only, Manufactured by GlaxoSmithKline Durham, NC 27701. NDC 0173-0869-10 recalled?

Yes. FDA published recall D-0160-2024 on January 3, 2024. Reported hazard: Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ANORO ELLIPTA.